...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease
【24h】

Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease

机译:膜相关的法呢基化的UCH-L1促进α-突触核蛋白的神经毒性,是帕金森氏病的治疗靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Ubiquitin C-terminal hydrolase-L1 (UCH-L1) is linked to Parkinson's disease (PD) and memory and is selectively expressed in neurons at high levels. Its expression pattern suggests a function distinct from that of its widely expressed homolog UCH-L3. We report here that, in contrast to UCH-L3, UCH-L1 exists in a membrane-associated form (UCH-L1~M) in addition to the commonly studied soluble form. C-terminal farnesylation promotes the association of UCH-L1 with cellular membranes, including the endoplasmic reticulum. The amount of UCH-L1~M in transfected cells is shown to correlate with the intracellular level of a-synuclein, a protein whose accumulation is associated with neurotoxicity and the development of PD. Reduction of UCH-L1~M in cell culture models of α-synuclein toxicity by treatment with a farnesyltransferase inhibitor (FTI-277) reduces α-synuclein levels and increases cell viability. Proteasome function is not affected by UCH-L1~M, suggesting that it may negatively regulate the lysosomal degradation of a-synuclein. Therefore, inhibition of UCH-L1 farnesylation may be a therapeutic strategy for slowing the progression of PD and related synucleinopathies.
机译:泛素C末端水解酶L1(UCH-L1)与帕金森氏病(PD)和记忆有关,并在神经元中高水平选择性表达。它的表达模式表明其功能不同于其广泛表达的同源物UCH-L3。我们在这里报告说,与UCH-L3相反,除了通常研究的可溶形式外,UCH-L1还以膜相关形式(UCH-L1〜M)存在。 C末端的法尼基化促进UCH-L1与细胞膜(包括内质网)的缔合。转染细胞中UCH-L1〜M的量与α-突触核蛋白的细胞内水平相关,α-突触核蛋白的积累与神经毒性和PD的发展有关。用法呢基转移酶抑制剂(FTI-277)处理可降低α-突触核蛋白毒性细胞培养模型中的UCH-L1〜M,从而降低α-突触核蛋白水平并提高细胞活力。蛋白酶体功能不受UCH-L1〜M影响,表明它可能对a-突触核蛋白的溶酶体降解产生负调控作用。因此,抑制UCH-L1法呢基化可能是减慢PD和相关突触核病进展的治疗策略。

著录项

  • 来源
  • 作者单位

    Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139 Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;

    Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139 Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;

    Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;

    Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;

    Laboratory of Neurogenetics, National Institutes of Health, Building 35, 9000 Rockville Pike, Bethesda, MD 20892;

    Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139;

    Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;

    Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139 Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    farnesylation; synuclein;

    机译:法呢基化;突触核蛋白;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号